Solomon SD, Lindsley K, Vedula SS, et al. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. Vascular endothelial growth factor and angiogenesis. Global prevalence of age-related macular degeneration and disease burden projection for 20: a systematic review and meta-analysis. Prevalence of age- related macular degeneration in the United States. Friedman DS, O'Colmain BJ, Muñoz B, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Klaver CC, Wolfs RC, Vingerling JR, et al. However, there are no statistically significant differences in changes of inner retinal layer thicknesses between two anti-VEGF agents. Conclusions: The thicknesses of all inner retinal layers diminish one year after anti-VEGF treatment of nAMD in both ranibizumab and aflibercept groups due to therapeutic effect obtained with fluid resorption, but not related to tissue loss. There was no statistically significant difference between ranibizumab and aflibercept groups. Ganglion cell layer thinning was significant at the end of 3 months, thinning of the inner nuclear layer was significant at the end of one year in both groups (p<0.05). There was a significant decrease in total retinal thickness in both groups at the end of 1 year (p=0.006 in ranibizumab, p=0.005 in aflibercept). Results: The ranibizumab group showed 3.85☑6.54 letters of increase and the aflibercept group showed 4.20☑6.30 letters of increase at the end of 1 year. Changes in each layer and comparison between ranibizumab and aflibercept groups were analyzed statistically during 1-year follow-up. Thicknesses of the total retina and inner retinal layers were measured by spectral-domain OCT in the central 1-mm diameter and surrounding 3-mm diameter rings of Early Treatment Diabetic Retinopathy Study grid. Materials and Methods: This retrospective, comparative study comprised 40 treatment-naive eyes of 40 patients treated with ranibizumab (20 eyes) or aflibercept (20 eyes) injections for nAMD. Purpose: To evaluate the changes of all inner retinal layers in eyes with neovascular age-related macular degeneration (nAMD) during anti- vascular endothelial growth factor (anti-VEGF) treatments and to compare two different anti-VEGF agents ranibizumab and aflibercept.
0 kommentar(er)
